• Provide preclinical consulting services that help clients navigate the drug discovery and development pipelines to develop innovative and exceptional products.• Design and pinpoint the precise models most appropriate for Biotechnology and Pharmaceutical companies’ drug development programs in immuno-oncology and other disease states.• Support companies in the immunology and oncology domain through all the preclinical phases of drug discovery and preclinical development for both small molecules and large biologics.

• Strengthen over 20 start-up companies’ commercial feasibility by applying my scientific and entrepreneur experience through my involvement in the MassBio/MassCONNECT program.• Advise MIT and Harvard University spin-out companies on pre-clinical development strategies to further their product through the drug development pipeline.

The Industry Committee is comprised of SITC members from the pharmaceutical and biotechnology industries. The mission of the Industry Committee is to push the field forward on a worldwide level, create community and present new data, particularly pre-clinical, to a growing and varied constituency.

• Promoted Caprion's immunologic and proteomic capabilities and technologies to biotechnology and pharmaceutical companies to help develop their drug candidates.• Boosted Caprion's visibility and generated new leads, such as Mount Sinai, through presentations, client visits, and publications, including contributing to a book chapter.

• Devised and managed proactive oncology research and development (R&D) activities including syngeneic, humanized, and PDX murine models. • Generated new revenue streams by presenting in vitro and in vivo pre-clinical drug development capabilities through client visits, webinars, and seminars.• Cultivated strong relationships with biotech and pharmaceutical clients in the US and Europe.• Evaluated external scientific opportunities with the view to integrate them into site portfolios.

• Directed and motivated a quality-oriented, 20-member scientific team utilizing in vitro and in vivo pre-clinical models with annual revenues of $3.8 million.• Conceived and implemented strategies that aimed to enhance visibility in a metrics focused manner by means of aggressive marketing, nationally and internationally.• Proactively directed research and development programs to generate income streams by introducing new technologies, such as angiogenesis assays, applying for grant funding, and maintaining customer satisfaction.

• Conceptualized and established a fully functioning research facility from a greenfield site focusing on cancer and angiogenesis.• Recruited and oversaw top-talent, 25-member scientific team, empowering members to proactively develop research projects.• Managed all aspects of the laboratory, securing monies for equipment and research projects, developing research projects, and overseeing budget and finances.• Successfully created and managed research projects that included identifying novel gene candidates for the potential diagnosis and treatment of pancreatic cancer.• Established a biobank with over 140 human pancreatic cancer tissues. • Designed translational medicine and angiogenesis courses for final year medical students

• Founded start-up biotechnology company that aimed to bring to market an effective immune-based anti-cancer therapy.• Developed and marketed novel a immunotherapy for cancer and inflammatory disorders based upon a discovery and preclinical development at Stanford University.• Strategic planner and dynamic innovator for developing company; creating business concepts, acquiring GMP facility, liaising with oncologists to carry out clinical trial, securing investment.

• Provided stewardship to an oncology-based drug company founded to develop a proprietary mass-customized bio-production process for manufacturing tumor antigen independent cytotoxic T-cell populations.• Active member of the Board of Directors responsible for developing immune modulatory technology cores, manufacturing, and quality assurance. • Orchestrated a cGMP ex-vivo cell expansion, harvesting, and shipping facility to develop and implement FDA compliant standard operating procedures.

• Initiated and drove projects focusing on the role of integrin driven cyclooxygenase (COX) regulation of angiogenesis and modulation by non-steroidal anti-inflammatory drugs (NSAIDs). • Supervised and provided direction to several PhD, MD and pre-medical students and lectured in cell cycle biology and cancer therapeutics to second year medical students.• Generated ideas and wrote grants quarterly to fund scientific projects.